1513.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 05:58):

Stats
Dagens volum	550 700
Gjennomsnittsvolum	657 790
Markedsverdi	34.00B
EPS	HKD0.500 ( 2023-10-24 )
Last Dividend	HKD1.744 ( 2023-07-04 )
Next Dividend	HKD0 ( N/A )
P/E	11.50
ATR14	HKD0.0140 (0.05%)

Volum Korrelasjon

Lang: 0.11 (neutral)

Kort: 0.00 (neutral)

Signal:(29.738) Neutral

Livzon Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Livzon Pharmaceutical Korrelasjon - Valuta/Råvare

0.10
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.11
( neutral )

0.07
( neutral )

-0.54
( weak negative )

Livzon Pharmaceutical Økonomi

Annual	2023
Omsetning:	HKD12.43B
Bruttogevinst:	HKD7.96B (64.08 %)
EPS:	HKD2.10

FY	2023
Omsetning:	HKD12.43B
Bruttogevinst:	HKD7.96B (64.08 %)
EPS:	HKD2.10

FY	2022
Omsetning:	HKD12.63B
Bruttogevinst:	HKD8.17B (64.68 %)
EPS:	HKD2.04

FY	2021
Omsetning:	HKD12.06B
Bruttogevinst:	HKD7.81B (64.75 %)
EPS:	HKD1.900

Financial Reports:

No articles found.

Livzon Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD1.744 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Livzon Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.77 - Stable (35.40%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.221	2014-07-08
Last Dividend	HKD1.744	2023-07-04
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	HKD9.31	--
Avg. Dividend % Per Year	0.00%	--
Score	3.13	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.77
Div. Directional Score	8.45	--

Next Divdend (Est)
(2024-06-24)

HKD1.912 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.13

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3866.HK	Ex Dividend Junior	2023-06-02	Annually	0.00%
1731.HK	Ex Dividend Junior	2023-06-23	Sporadic	0.00%
0771.HK	Ex Dividend Junior	2023-05-31	Sporadic	0.00%
2327.HK	Ex Dividend Junior	2023-08-03	Sporadic	0.00%
1290.HK	Ex Dividend Junior	2023-06-14	Sporadic	0.00%
0363.HK	Ex Dividend Knight	2023-06-01	Annually	0.00%
6117.HK	Ex Dividend Junior	2023-05-22	Sporadic	0.00%
1857.HK	Ex Dividend Junior	2023-08-23	Semi-Annually	0.00%
0881.HK	Ex Dividend Junior	2023-06-23	Annually	0.00%
0026.HK	Ex Dividend Junior	2023-10-03	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.161	1.500	6.77	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0786	1.200	7.38	8.86	[0 - 0.3]
returnOnEquityTTM	0.142	1.500	9.53	10.00	[0.1 - 1]
payoutRatioTTM	0.799	-1.000	2.01	-2.01	[0 - 1]
currentRatioTTM	2.06	0.800	4.69	3.75	[1 - 3]
quickRatioTTM	1.802	0.800	4.11	3.29	[0.8 - 2.5]
cashRatioTTM	1.338	1.500	3.68	5.52	[0.2 - 2]
debtRatioTTM	0.141	-1.500	7.64	-10.00	[0 - 0.6]
interestCoverageTTM	24.70	1.000	1.962	1.962	[3 - 30]
operatingCashFlowPerShareTTM	3.15	2.00	8.95	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.27	2.00	8.87	10.00	[0 - 20]
debtEquityRatioTTM	0.244	-1.500	9.02	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.645	1.000	2.58	2.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.206	1.000	7.88	7.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.827	1.000	6.51	6.51	[0.2 - 2]
assetTurnoverTTM	0.487	0.800	-0.0887	-0.0709	[0.5 - 2]
Total Score				10.13

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.47	1.000	8.94	0	[1 - 100]
returnOnEquityTTM	0.142	2.50	9.70	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.27	2.00	9.24	10.00	[0 - 30]
dividendYielPercentageTTM	7.18	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.15	2.00	8.95	10.00	[0 - 30]
payoutRatioTTM	0.799	1.500	2.01	-2.01	[0 - 1]
pegRatioTTM	1.075	1.500	6.17	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.241	1.000	6.49	0	[0.1 - 0.5]
Total Score				6.77

Livzon Pharmaceutical

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.